Syenza News — health technology assessment, market access and health economics

Novartis core operating income rises, 2026 outlook raised
Novartis core operating income rose 10% at constant exchange rates in Q3 2026, and 2026 guidance for the measure was raised. #SyenzaNews #MarketAccess
Recent Posts

Izalontamab brengitecan breast cancer: 59% lower risk of progression
Oct 27
Keytruda Monotherapy Endometrial Cancer: 43% Risk Reduction
Oct 27
Endometriosis and fibroid tablets in England: prescriptions soar
Oct 27
JNJ-6143 prostate cancer: 75% tumor response in Phase 1 trial
Oct 26
Claudin 18.2 antibody-drug conjugate prolongs survival in gastro-oesophageal cancer
Oct 26Syenza's Top Picks

Semaglutide for Opioid Use Disorder: $13.3M Trial Planned in Allegheny County
Oct 15, 2026
Jemperli rectal cancer approval may let some patients skip standard treatment
Oct 20, 2026
Adverse reaction reports in Portugal rise with GLP-1 use
Oct 19, 2026
Foundayo Oral GLP-1 Tablet Gets Positive EU Opinion
Oct 19, 2026
EMA Draft Reflection Paper Sets Rules for Confirmatory Platform Trials
Oct 19, 2026
Reinforcement learning rTMS for depression treatment
Oct 19, 2026Latest News

Diseases
Obesity drug reimbursement in Portugal: new SNS terms
Portaria n.º 464/2026/1 limits state reimbursement for obesity medicines to SNS patients in a hospital obesity pathway. Cover is 15% for 12 months. #SyenzaNews #MarketAccess

Diseases Free account
Antiretroviral Tender Awards Declared Invalid by Pretoria Court
A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla’s review succeeded on all five grounds, while Hetero’s challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV

Clinical Practice
Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%
Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess

Alzheimer's Disease
FDA Launches Neuroscience Medical Product Development Program
The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer’s Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess

Artificial Intelligence And Machine Learning
Clinical AI governance framework guides AI tool evaluation
A new npj Digital Medicine article in press from SCPMG proposes the C-TACT clinical AI governance framework, with weighted lifecycle scorecards and its limits stated.

Clinical Practice
Palbociclib Maintenance in HER2-Positive Breast Cancer: EMA Withdrawal
Pfizer has withdrawn its EU application for palbociclib in HER2-positive breast cancer. EMA questioned the open-label PATINA endpoint.

Clinical Practice
Health Economists in Clinical Trials: Why Early Engagement Matters
Health economists in clinical trials are most useful when they join early, explain their methods in plain language and plan for the data they will need. That was the central message of a webinar brought together by University College London and the Global Health Network at the University of Oxford. A professor of health policy and systems management in Uganda moderated three panelists with trial experience across Africa and Asia. Why trials need economic questions The moderator framed the session […]

Big Data Analysis
New Drug Launch Prices Stay High While Patients Wait for Access
New drug launch prices are still high. ICER’s 2026 Launch Price and Access Report finds the median net price for 2025 approvals was about $257,000, and only about one in three new prescriptions was filled within 30 days. #SyenzaNews #MarketAccess #HEOR

Clinical Practice
CagriSema Weight Loss in Women: Menopause Stages in REDEFINE 1
Two post hoc REDEFINE 1 analyses show CagriSema weight loss in women held across premenopausal, perimenopausal and postmenopausal stages. #SyenzaNews #obesity #MarketAccess

Health Policy Free account
Medicaid Provider Taxes Raise Private Insurance Premiums, ASPE Finds
ASPE finds Medicaid hospital provider taxes raised employer premiums 1.5 to 1.7 percent, and the 2025 WFTC law is projected to cut them further.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.




